{[ promptMessage ]}

Bookmark it

{[ promptMessage ]}

DDI09.SS.PharmaDA.wave4

DDI09.SS.PharmaDA.wave4 - Dartmouth 2K9 1 Pharma D/A Pharma...

Info iconThis preview shows pages 1–4. Sign up to view the full content.

View Full Document Right Arrow Icon
34ba03ff93f9806cd5f0191fb16f7418ed0776e6.doc Dartmouth 2K9 1 Pharma D/A Pharma D/A ............................................................................................................................................... 1 1NC .......................................................................................................................................................... 2 UniquenessExt. ......................................................................................................................................... 4 Link ext ..................................................................................................................................................... 5 Bioterror Internal Link Ext .......................................................................................................................... 6 Bioterror Impact Ext. ................................................................................................................................. 7 Innovation 2NC .......................................................................................................................................... 8 Econ 2NC .................................................................................................................................................. 9 Last printed 1
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
34ba03ff93f9806cd5f0191fb16f7418ed0776e6.doc Dartmouth 2K9 2 1NC Despite the recent economic downturn U.S. pharmaceutical companies are still experiencing high growth Reuters ‘9 (May 13 th 2009, Reuters, ‘Learns about the U.S. pharmaceutical Industry Report, 2008-2009, http://www.reuters.com/article/pressRelease/idUS140811+13-May-2009+BW20090513 ) The United States has the largest pharmaceutical industry in the world . In 2007, its pharmceutical revenue totaled at US$ 315 billio n. In the past decades, the structure of American pharmaceutical industry has changed dramatically caused by the aging of population, the emerging of bio-pharmaceutical technology and fierce global competition. The key players in the United States including Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck, etc. American pharmaceutical companies paid great attention to R & D due to the free market competition and patent protection of new medicines in the US. Since the year of 2000, the pharmaceutical R & D expenditure has been maintaining an increase, even in 2008, impacted by the global financial crisis, the pharmaceutical R & D expenditure totaled at US $65.2 billion, up 3.16% of last year. Healthcare reform collapses the pharmaceutical industry The Economist, ’08 (December 13, 2008, Winds of change; Pharmaceuticals, lexis) Perhaps surprisingly, PhRMA now supports most aspects of health-care reform being mooted, from universal coverage to restructuring the insurance market. However, this acceptance of change goes only so far. Push Merck officials on the prospects for drug-price controls , and their unflinching answer is that they are "completely opposed" to such European-style " rationing" of care. The industry makes much of its profit in the unfettered American market, and price controls threaten that flow of cash . It argues that if limits are imposed on drug prices in America, there will be less to invest in innovation and everyone will suffer , since the rest of the world free-rides on American spending. That argument is correct, in that businesses need the prospect of profit in order to invest . In practice, though, America is unlikely to impose draconian price controls. The more likely outcome is that government health schemes will start demanding discounts from drugs firms, and will buy more generics. Dr Anderson has crunched the numbers, and he reckons this need not lead to disaster. He reckons that a 20% cut in drugs prices paid by Medicare, America's health-care system for the old and disabled, will shave profits at the biggest drugs firms by a mere 5%. Last printed 2
Background image of page 2
34ba03ff93f9806cd5f0191fb16f7418ed0776e6.doc Dartmouth 2K9 3 The Pharmaceutical Industry is key to preventing bioterrorism Washington Post ‘1 (Justin Gillis, 2001 "Scientists Race for Vaccines," lexis) U.S. scientists, spurred into action by the events of Sept. 11, have begun a concerted assault on bioterrorism, working to produce an array of new medicines that include treatments for smallpox, a safer smallpox vaccine and a painless anthrax vaccine. At least
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
Image of page 4
This is the end of the preview. Sign up to access the rest of the document.

{[ snackBarMessage ]}